This is a preview. For optimal viewing please subscribe to iTunes or download file on your PC. Do you want to continue.
Do not show again
| Author | H. Drexler, Hannover (DE) |
|---|---|
| Title | Viewpoint: 1 - The future in heart failure management will be driven by biomarkers |
| Shownotes | "Preferably biomarkers should be able to identify patients that have HF, identify his or her risk and monitor treatment effects. BNP has the ability to identify HF, serve as a prognostic marker and can be used to guide therapy. Also serial measurements of Troponin T can identify high risk patients. Novel biomarkers, such as GDF-15, are showing promising results, paving the way for multi-marker strategies." |